cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 23:00:00 28/08/2026 +03			5-day change	1st Jan Change
0.5000 ^USD	+0.58%		-1.75%	-62.96%

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-14	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

Last Transcript : cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-14

More transcripts

Analysts' recommendations : cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors : cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	$0.5000	+0.58%	153,733
27/08/26	$0.4971	-4.42%	36,956
26/08/26	$0.5201	+0.41%	20,901
25/08/26	$0.5180	+6.15%	191,896
24/08/26	$0.4880	-4.11%	51,903

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.5000

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	5.6M 4.83M 4.53M 4.13M 7.78M 535M 7.81M 53.7M 20.95M 270M 21.03M 20.58M 896M	P/E 2026 *	-1.52x	P/E 2027 *	-1.35x
Enterprise Value	5.6M 4.83M 4.53M 4.13M 7.78M 535M 7.81M 53.7M 20.95M 270M 21.03M 20.58M 896M	EV / Sales 2026 *	0.26x	EV / Sales 2027 *	0.24x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-14	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
08-13	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-15	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-15	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-15	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
04-01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI

08-13	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR
07-27	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ
07-24	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	PR

1 day	+0.58%
1 week	-1.75%
Current month	-1.36%
3 months	-39.47%
6 months	-45.46%
Current year	-62.96%

1 week	0.48	0.53
1 month	0.46	0.62
Current year	0.46	1.34
1 year	0.46	2.56
3 years	0.46	13.84
5 years	0.46	882
10 years	0.46	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation : cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript : cbdMD, Inc.

Analysts' recommendations : cbdMD, Inc.

Press Releases : cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/14/26 A	Jeffrey Porter	Free	Director	1,572	0.0150%
4/14/26 A	William Raines	Free	Director	1,572	0.0150%
4/14/26 A	Bakari Sellers	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+0.58%	-1.75%	-35.48%	-94.05%	5.6M
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.47%	+112.05%	1,047B
JOHNSON & JOHNSON	+0.85%	-0.81%	+52.77%	+63.15%	646B
ABBVIE INC.	-1.03%	-3.58%	+22.87%	+73.29%	451B
ROCHE HOLDING AG	-1.46%	-4.50%	+37.43%	+38.41%	355B
NOVARTIS AG	-0.72%	-2.89%	+21.86%	+36.79%	291B
ASTRAZENECA PLC	-1.19%	-2.21%	+1.35%	+12.29%	252B
AMGEN INC.	-1.05%	-1.57%	+51.40%	+68.55%	234B
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.29%	203B
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+29.42%	+89.10%	181B
Average	-0.63%	-2.58%	+22.45%	+34.53%	365.93B
Weighted average by Cap.	-0.48%	-3.46%	+38.66%	+65.51%

	2026 *	2027 *
Net sales	21.92M 18.89M 17.71M 16.17M 30.46M 2.1B 30.56M 210M 81.99M 1.06B 82.31M 80.52M 3.51B	22.92M 19.75M 18.52M 16.9M 31.84M 2.19B 31.94M 220M 85.71M 1.11B 86.05M 84.17M 3.67B
Net income	-3.33M -2.87M -2.69M -2.46M -4.63M -318M -4.64M -31.94M -12.46M -161M -12.51M -12.24M -533M	-4.03M -3.47M -3.25M -2.97M -5.6M -385M -5.61M -38.6M -15.06M -194M -15.12M -14.79M -644M
Net Debt	-	-